Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 3;13(6):e70217.
doi: 10.1002/rcr2.70217. eCollection 2025 Jun.

Diagnostic Dilemma in a Case of Anti-PL-7 Antibody-Positive Interstitial Lung Disease: When Autoimmune Alveolar Proteinosis Masquerades as Anti-Synthetase Syndrome

Affiliations

Diagnostic Dilemma in a Case of Anti-PL-7 Antibody-Positive Interstitial Lung Disease: When Autoimmune Alveolar Proteinosis Masquerades as Anti-Synthetase Syndrome

Beili Liu et al. Respirol Case Rep. .

Abstract

Pulmonary alveolar proteinosis (PAP) and anti-PL-7 antibody-positive interstitial lung disease (ILD) share early radiographic similarities, yet their treatments differ significantly. This article reports a rare case of dual anti-PL-7 and anti-GM-CSF autoantibody positivity, initially misdiagnosed as anti-synthetase syndrome due to interstitial infiltrates and concurrent Nocardia/Aspergillus infections. Empirical glucocorticoid therapy worsened symptoms. Definitive PAP diagnosis was confirmed via milky bronchoalveolar lavage fluid (BALF) and anti-GM-CSF autoantibody detection, alongside incidental pulmonary embolism. Multidisciplinary intervention (antimicrobials, thrombolysis, and whole-lung lavage) improved oxygenation. Clinicians must consider PAP as a differential diagnosis in patients with atypical presentations before commencing immunosuppressive therapy. Multidisciplinary collaboration is crucial for managing complex PAP cases.

Keywords: anti‐GM‐CSF autoantibody; anti‐PL‐7 antibody; multidisciplinary intervention; pulmonary alveolar proteinosis; steroid.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Dynamic evolution of the patient's pulmonary imaging: (A) The initial chest CT scan shows diffuse interstitial changes in both lungs accompanied by patchy ground‐glass opacities, and mild enlargement of the mediastinal lymph nodes. (B) Two months later, the re‐examination shows a reduction in the solid nodules in both lungs, but an increase in interstitial exudation in the lower lobes. (C) After misdiagnosis of RP‐ILD and treatment with glucocorticoids plus voriconazole, a typical ‘road‐paving stone sign’ with small interlobular septal grid‐like thickening is observed. (D) After total lung lavage, the lesions show significant absorption. (E, F) After sequential GM‐CSF nebulisation treatment for 1 and 3 months, the exudation improves progressively. Diagnosis and treatment process of combined intracranial Nocardia infection. (G) The initial enhanced MRI scan shows a ring‐shaped enhanced abscess in the right parietal lobe (arrow). (H) After 2 months of treatment with sulphonamides combined with linezolid, the lesion is absorbed. Figure (I) shows PAS staining (+), suggesting glycoprotein deposition (arrow).

References

    1. McCarthy C., Bonella F., O'Callaghan M., et al., “European Respiratory Society Guidelines for the Diagnosis and Management of Pulmonary Alveolar Proteinosis,” European Respiratory Journal 64, no. 5 (2024): 2400725. - PubMed
    1. Hervier B., Uzunhan Y., Hachulla E., et al., “Antisynthetase Syndrome Positive for Anti‐Threonyl‐tRNA Synthetase (Anti‐PL7) Antibodies,” European Respiratory Journal 37, no. 3 (2011): 714–717. - PubMed
    1. Akasaka K., Tanaka T., Kitamura N., et al., “Outcome of Corticosteroid Administration in Autoimmune Pulmonary Alveolar Proteinosis: A Retrospective Cohort Study,” BMC Pulmonary Medicine 15 (2015): 88. - PMC - PubMed
    1. Ishimoto H., Sakamoto N., Yura H., et al., “Autoimmune Pulmonary Alveolar Proteinosis Exacerbated by Steroid Therapy due to Misdiagnosis as Anti‐Aminoacyl‐tRNA Synthetase (ARS) Antibody Positive‐Interstitial Pneumonia: A Case Report,” BMC Pulmonary Medicine 22, no. 1 (2022): 120. - PMC - PubMed
    1. Labirua‐Iturburu A., Selva‐O'Callaghan A., Vincze M., et al., “Anti‐PL‐7 (Anti‐Threonyl‐tRNA Synthetase) Antisynthetase Syndrome: Clinical Manifestations in a Series of Patients From a European Multicenter Study (EUMYONET) and Review of the Literature,” Medicine (Baltimore) 91, no. 4 (2012): 206–211. - PubMed

LinkOut - more resources